Immunogenicity, Reactogenicity, and Safety of a Second Booster with BNT162b2 or Full-Dose Mrna-1273: A Randomized VACCELERATE Trial in Adults Aged ≥75 Years (EU-COVAT-1-AGED Part B) Jannik Stemler , Lusine Yeghiazaryan , Christoph Stephan , Kristin Greve-Isdahl Mohn , Antonio-Jose Carcas-Sansuan , Esperanza Romero Rodriguez , Jose Molto , Itziar Vergara Mitxeltorena , Tobias Welte , Birute Zablockiene , Murat Akova , Ullrich Bethe , Sarah Heringer , Jon Salmanton-Garcia , Julia Jeck , Lea Tischmann , Marouan Zarrouk , Arnd Cueppers , Lena M. Biehl , Jan Grothe , Sibylle C. Mellinghoff , Julia A. Nacov , Julia M. Neuhann , Rosanne Sprute , Jesus Frias-Iniesta , Riya Negi , Colette Gaillard , Gurvin Saini , Alejandro Garcia Leon , Patrick W. G. Mallon , Christine Lammens , An Hotterbeekx , Katherine Loens , Surbhi Malhotra-Kumar , Herman Goossens , Samir Kumar-Singh , Franz Koenig , Martin Posch , Philipp Koehler , Oliver A. Cornely INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES（2024）
关键词
SARS-CoV-2, Advanced age, Booster vaccination, Immunosenescence, Variants of concern, Neutralizing antibodies
AI 理解论文
溯源树
样例
